Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Alvotech ( (ALVO) ) is now available.
On December 19, 2025, Alvotech reported that it and its U.S. commercial partner Teva Pharmaceuticals have reached a settlement and license agreement with Regeneron Pharmaceuticals covering AVT06, Alvotech’s proposed biosimilar to the eye drug Eylea (aflibercept), setting a licensed U.S. market entry date in the fourth quarter of 2026, or earlier under certain conditions, pending FDA approval. The deal, which follows AVT06 marketing approvals in the UK, Japan and the European Economic Area and positive 2024 phase 3 data in wet age-related macular degeneration, secures a clear U.S. launch pathway for Alvotech’s aflibercept biosimilar, strengthening its and Teva’s positioning in the high-value retinal disease market and potentially intensifying future price competition for stakeholders once the product can be introduced in the United States.
The most recent analyst rating on (ALVO) stock is a Sell with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s overall stock score is driven by financial instability, bearish technical indicators, and regulatory challenges impacting short-term outlook. While strategic investments and historical growth are positives, significant risks remain.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a Luxembourg- and Iceland-based biotechnology company focused solely on developing and manufacturing biosimilar medicines for patients worldwide. With a fully integrated platform and broad in-house capabilities, the company is building a pipeline of eight disclosed biosimilar candidates targeting autoimmune disorders, eye disease, osteoporosis, respiratory disease and cancer, and distributes through a network of commercial partnerships that provide reach across the United States, Europe, Japan, China, other Asian markets and large parts of South America, Africa and the Middle East.
Average Trading Volume: 591,575
Technical Sentiment Signal: Sell
Current Market Cap: $1.46B
See more data about ALVO stock on TipRanks’ Stock Analysis page.